Form 4: United Therapeutics CFO Executes Pre-Arranged Stock Option Exercise and Sale

United Therapeutics Corporation's CFO and Treasurer, James Edgemond, exercised stock options and sold 12,000 shares of common stock on June 9, 2025, as part of a pre-arranged 10b5-1 trading plan.

Summary

• James Edgemond, CFO and Treasurer of United Therapeutics Corp (UTHR), engaged in a series of transactions on June 9, 2025.
• He exercised 12,000 stock options at an exercise price of $117.76 per share.
• Concurrently, he sold all 12,000 shares of common stock acquired from the option exercise at weighted average prices ranging from $325.2037 to $328.28 per share.
• These transactions were conducted under a pre-arranged Rule 10b5-1 trading plan established on November 6, 2024.
• Following these transactions, Mr. Edgemond's direct beneficial ownership of common stock decreased from 20,118 shares to 8,118 shares.
• He retains 87,500 derivative securities (stock options).

Sentiment

Score: 6

Explanation: While insider selling can sometimes be viewed negatively, the fact that these transactions were conducted under a pre-arranged 10b5-1 plan mitigates concerns that the sales are based on negative undisclosed information. It's a routine executive compensation event.

Positives

• The transactions were executed under a pre-arranged Rule 10b5-1 plan, indicating the sales were not based on new, non-public information and were scheduled in advance.
• The exercise of stock options at $117.76 and subsequent sale at prices over $325 demonstrates a significant profit for the executive on these specific shares.

Negatives

• The CFO sold a substantial number of shares (12,000), reducing his direct beneficial ownership of common stock by 12,000 shares.

Future Outlook

NA

Industry Context

This Form 4 filing details an individual executive's pre-planned stock transactions and does not provide broader industry context or trends.

Stakeholder Impact

• Shareholders: The sale of shares by a key executive, even if pre-planned, might be viewed with slight caution, but the 10b5-1 plan reduces the negative implication. The reduction in direct beneficial ownership could be seen as a minor decrease in alignment, though the executive still holds a significant number of options.

Key Dates

Recommendation

Keywords

United Therapeutics, UTHR, SEC Form 4, Insider Trading, Stock Option Exercise, Share Sale, 10b5-1 Plan, Executive Compensation, CFO, James Edgemond